Johnson & Johnson (NYSE:JNJ) EVP Jennifer L. Taubert Sells 59,397 Shares of Stock

Johnson & Johnson (NYSE:JNJGet Free Report) EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $157.87 on Tuesday. The company’s fifty day moving average is $158.18 and its 200-day moving average is $158.62. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The firm has a market cap of $380.04 billion, a price-to-earnings ratio of 11.43, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same quarter in the prior year, the business posted $2.35 EPS. Johnson & Johnson’s quarterly revenue was down 9.7% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be paid a $1.19 dividend. The ex-dividend date is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s payout ratio is presently 34.47%.

Analyst Upgrades and Downgrades

Several analysts recently commented on JNJ shares. Raymond James increased their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Tuesday, February 6th. Finally, TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $176.14.

Get Our Latest Stock Analysis on JNJ

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC boosted its holdings in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $4,609,399,000. Capital International Investors lifted its holdings in shares of Johnson & Johnson by 62.7% during the 2nd quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock worth $4,605,627,000 after acquiring an additional 10,724,110 shares during the period. Journey Strategic Wealth LLC lifted its holdings in shares of Johnson & Johnson by 161,420.2% during the 2nd quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock worth $1,204,404,000 after acquiring an additional 7,271,978 shares during the period. Finally, Morgan Stanley lifted its holdings in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after acquiring an additional 4,521,062 shares during the period. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Articles

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.